# Tirzepatide

Tirzepatide has 234 registered human trials. It is marketed for 2 different uses.

**In short**

- 234 registered human trials exist for Tirzepatide.
- Tirzepatide is FDA-approved — FDA-approved for type 2 diabetes and chronic weight management..
- What has actually been studied: adults with simple obesity, human immunodeficiency virus (hiv), metabolic dysfunction associated steatotic liver disease.
- Last checked against ClinicalTrials.gov on 2026-07-27.

## What it is sold for

- Weight loss
- Blood sugar control

## What has actually been tested

- Adults With Simple Obesity
- Human Immunodeficiency Virus (HIV)
- Metabolic Dysfunction Associated Steatotic Liver Disease
- Dyslipidaemia
- Diabetes Mellitus
- Obesity & Overweight
- Metabolic Syndrome
- Endometrial Cancer
- Atypical Hyperplasia
- Diabetes Mellitus, Type 2
- Diabetes
- Type 2 Diabetes
- Pre Diabetes
- Cannabis Use Disorder
- Obesity
- Overweight and Obesity
- Overweight
- Psoriatic Arthritis (PsA)
- Autosomal Dominant Polycystic Kidney
- Obesity Adult Onset
- Type 2 Diabetes Mellitus
- Alcohol Use Disorder (AUD)
- Overweight or Obese
- Comorbidities and Coexisting Conditions
- Type 2 Diabetes (Adult Onset)
- Breast Cancer
- Breast Neoplasms
- Breast Cancers
- Musculoskeletal Abnormalities
- Sarcopenic Obesity
- Osteoporosis
- Drug Effect
- Adult Congenital Heart Disease
- Healthy
- Dyspnea
- Quality of Life
- Renal Insufficiency
- End Stage Renal Disease
- Type II Diabetes
- Atherosclerosis
- Methamphetamine Use Disorder
- Cocaine Use Disorder
- Stimulant Use Disorders
- OSA
- Liver Cirrhoses
- Portal Hypertension Related to Cirrhosis
- Severe Obesity
- TIPS
- Weight Loss
- Knee Osteoarthritis
- Osteoarthritis, Knee
- Neuropathy, Small Fiber
- Diabete Mellitus
- Type2 Diabetes
- T2D
- T2DM (Type 2 Diabetes Mellitus)
- Glucose Metabolism Disorders
- Endocrine System Diseases
- Metabolic Disease
- Tirzepatide
- Acute Lymphoblastic Leukemia
- Diabetes Type 2
- Dietary Change
- Food Acceptance
- Cardiovascular Diseases
- Lax Skin
- Obesity (Disorder)
- Pancreatectomy; Hyperglycemia
- Smoking Cessation
- Smoking Behaviors
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Mild Autonomous Cortisol Secretion (MACS)
- Adrenalectomy; Status
- Psoriasis
- Overweight or Obesity
- Endometrial Intraepithelial Neoplasia
- Grade 1 Endometrial Endometrioid Carcinoma
- Atrial Fibrillation Ablation
- Persistent Atrial Fibrillation
- Overweight or Obesity; Type 2 Diabetes
- Weight Loss Maintenance
- Hormone-receptor-positive Breast Cancer
- Early Breast Cancer
- Obesity and Overweight
- Crohn Disease (CD)
- Hepatic Insufficiency
- Psoriatic Arthritis
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Non-Alcoholic Fatty Liver Disease
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Liver Fibrosis
- Metabolic Alcohol-associated Liver Disease
- Alcohol Use Disorder
- Chronic Kidney Disease
- Obesity and Obesity-related Medical Conditions
- Hypoglycemia
- Atrial Fibrillation
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Non-alcoholic Steatohepatitis
- Liver Fat
- Crohn's Disease
- Obesity or Overweight
- Heart Failure
- Diabete Type 2
- Arterial Hypertension
- Obesity Prevention
- Sarcopenia in Elderly
- Cardiovascular Function
- GLP - 1
- Chronic Disease
- Obesity &Amp; Overweight
- Digestive Disorders
- Type 1 Diabetes
- Type 1 Diabetes Mellitus
- T1D
- T1DM
- T1DM - Type 1 Diabetes Mellitus
- Overweight With One Weight Related Comorbidity
- Bone Disease, Metabolic
- Polycystic Ovary Syndrome (PCOS)
- Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
- Catheter Ablation
- Obesity-related Male Infertility
- Ulcerative Colitis
- Binge Eating Disorder
- HFpEF - Heart Failure With Preserved Ejection Fraction
- Diabetic Cardiomyopathies
- Type2diabetes
- Endometrioid Endometrial Adenocarcinoma
- Opioid Use Disorder
- Opioid Use Disorder, Moderate
- Opioid Use Disorder, Severe
- Hormone Receptor-Positive Breast Cancer
- HER2-Negative Breast Cancer
- Obesity Recidivism
- GLP-1
- Ablation Techniques
- Body Composition
- Bariatric Surgery
- Lipodystrophy, Partial
- Cannabis Use Disorder, Moderate
- Cannabis Use Disorder, Severe
- Colorectal Cancer Prevention
- Colorectal Adenoma
- Heart Failure, Diastolic
- Heart Failure With Preserved Ejection Fraction
- Weight Gain
- Weight Maintenance
- Prostate Carcinoma
- Recurrent Prostate Carcinoma
- Obese Patients
- Gastroparesis
- Weight Change Trajectory
- Weight Change, Body
- Drug Discontinuation
- Substance Use Disorders
- Eating Behavior Changes
- MASLD
- Metabolism and Nutrition Disorder
- Triglycerides
- Weight Gain Trajectory
- Cholesterol, Elevated
- Adolescent Obesity
- Body-Weight Trajectory
- Weight Loss Trajectory
- Anti-obesity Agents
- Prader-Willi Syndrome
- Hypothalamic Obesity
- Obesity/Therapy
- Prostate Cancer
- Coronary Artery Disease
- Coronary Microvascular Dysfunction
- Stable Angina Pectoris
- Chronic Coronary Artery Disease
- Atherosclerosis Cardiovascular Disease
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Idiopathic Intracranial Hypertension (IIH)
- Wolfram Syndrome
- Depression
- Alcohol
- Obesity and Metabolic Syndrome
- Muscle Mass and Strength
- Physical Function
- Menopause
- Type 2 Diabetes Mellitus (T2DM)
- Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
- Alcohol Abuse/Dependence
- Alcohol Dependence
- Alcoholism
- Schizophrenia Disorders
- Schizophrenia and Disorders With Psychotic Features
- Schizophrenia and Schizophrenia Spectrum Psychosis
- Schizophrenia
- Type 1 Diabetes (T1D)
- Obstructive Sleep Apnea
- Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- Hypertension
- HIV
- Chronic Inflammation
- Overweight , Obesity
- Menopause Hot Flashes
- Hidradenitis Suppurativa
- Long COVID
- Nonalcoholic Steatohepatitis
- Healthy Subjects
- BMI Greater Than 30
- Crohn Disease
- Type1diabetes
- Sarcopenia
- Aging
- LONGEVITY 1

## Every trial on record

| Trial ID | Title | Condition | Phase | Status | Enrolled |
|---|---|---|---|---|---|
| [NCT07293325](https://clinicaltrials.gov/study/NCT07293325) | Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | Adults With Simple Obesity | Not phased | RECRUITING | 66 |
| [NCT07707778](https://clinicaltrials.gov/study/NCT07707778) | Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV | Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease | Phase 4 | ENROLLING_BY_INVITATION | 60 |
| [NCT06073184](https://clinicaltrials.gov/study/NCT06073184) | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium | Endometrial Cancer, Atypical Hyperplasia | Phase 2 | NOT_YET_RECRUITING | 71 |
| [NCT06657209](https://clinicaltrials.gov/study/NCT06657209) | Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide | Diabetes Mellitus, Type 2, Diabetes | Phase 4 | RECRUITING | 104 |
| [NCT07265752](https://clinicaltrials.gov/study/NCT07265752) | Tirzepatide for the Treatment of Cannabis Use Disorder | Cannabis Use Disorder | Phase 2 | NOT_YET_RECRUITING | 6 |
| [NCT05912621](https://clinicaltrials.gov/study/NCT05912621) | Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity | Obesity, Overweight and Obesity | Phase 2 | RECRUITING | 66 |
| [NCT07443956](https://clinicaltrials.gov/study/NCT07443956) | Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis | Psoriatic Arthritis (PsA), Obesity & Overweight | Not phased | RECRUITING | 45 |
| [NCT06582875](https://clinicaltrials.gov/study/NCT06582875) | Glucagon-Like Peptide-1 Receptor Agonist in ADPKD | Autosomal Dominant Polycystic Kidney, Obesity | Phase 2 | RECRUITING | 126 |
| [NCT07671391](https://clinicaltrials.gov/study/NCT07671391) | A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants | Obesity Adult Onset | Phase 2 | NOT_YET_RECRUITING | 60 |
| [NCT05553093](https://clinicaltrials.gov/study/NCT05553093) | Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 4 | RECRUITING | 150 |
| [NCT07292519](https://clinicaltrials.gov/study/NCT07292519) | Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) | Alcohol Use Disorder (AUD), Overweight or Obese | Phase 2 | NOT_YET_RECRUITING | 46 |
| [NCT06893211](https://clinicaltrials.gov/study/NCT06893211) | Effect of Tirzepatide on Brown Adipose Tissue in Obesity | Obesity | Phase 2 | COMPLETED | 34 |
| [NCT06246799](https://clinicaltrials.gov/study/NCT06246799) | Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes | Type 2 Diabetes (Adult Onset) | Phase 3 | RECRUITING | 256 |
| [NCT06517212](https://clinicaltrials.gov/study/NCT06517212) | Tirzepatide Weight Loss for MRD+ Early Breast Cancer | Breast Cancer, Breast Neoplasms | Phase 2 | RECRUITING | 48 |
| [NCT07154719](https://clinicaltrials.gov/study/NCT07154719) | GLP-1R Actions on Muscle and the Skeleton | Musculoskeletal Abnormalities, Obesity | Phase 4 | ACTIVE_NOT_RECRUITING | 50 |
| [NCT07354880](https://clinicaltrials.gov/study/NCT07354880) | Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease | Obesity & Overweight, Adult Congenital Heart Disease | Phase 4 | NOT_YET_RECRUITING | 30 |
| [NCT06890611](https://clinicaltrials.gov/study/NCT06890611) | A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants | Healthy | Phase 1 | COMPLETED | 125 |
| [NCT05812183](https://clinicaltrials.gov/study/NCT05812183) | Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity | Dyspnea, Quality of Life | Phase 4 | WITHDRAWN | 0 |
| [NCT03482024](https://clinicaltrials.gov/study/NCT03482024) | A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function | Renal Insufficiency, End Stage Renal Disease | Phase 1 | COMPLETED | 45 |
| [NCT05708859](https://clinicaltrials.gov/study/NCT05708859) | Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT | Type II Diabetes, Atherosclerosis | Phase 4 | RECRUITING | 120 |
| [NCT07693608](https://clinicaltrials.gov/study/NCT07693608) | An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder | Obesity, Methamphetamine Use Disorder | Phase 2 | NOT_YET_RECRUITING | 45 |
| [NCT04255433](https://clinicaltrials.gov/study/NCT04255433) | A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 13299 |
| [NCT06400615](https://clinicaltrials.gov/study/NCT06400615) | Study That Tests AD109 in Patients Taking GLP-1 Drugs | OSA | Phase 2 | COMPLETED | 40 |
| [NCT05822830](https://clinicaltrials.gov/study/NCT05822830) | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Obesity, Overweight | Phase 3 | COMPLETED | 751 |
| [NCT06801015](https://clinicaltrials.gov/study/NCT06801015) | Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions | Obesity | Phase 4 | ACTIVE_NOT_RECRUITING | 30 |
| [NCT07058155](https://clinicaltrials.gov/study/NCT07058155) | Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease | Liver Cirrhoses, Portal Hypertension Related to Cirrhosis | Phase 4 | RECRUITING | 70 |
| [NCT07700030](https://clinicaltrials.gov/study/NCT07700030) | High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE) | Weight Loss | Not phased | NOT_YET_RECRUITING | 32 |
| [NCT06191848](https://clinicaltrials.gov/study/NCT06191848) | Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) | Obesity, Knee Osteoarthritis | Phase 4 | RECRUITING | 352 |
| [NCT07706088](https://clinicaltrials.gov/study/NCT07706088) | Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy | Neuropathy, Small Fiber, Diabete Mellitus | Phase 4 | NOT_YET_RECRUITING | 40 |
| [NCT05260021](https://clinicaltrials.gov/study/NCT05260021) | A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both | Type2 Diabetes, Diabetes Mellitus | Phase 3 | COMPLETED | 99 |
| [NCT06047548](https://clinicaltrials.gov/study/NCT06047548) | A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Overweight, Obesity | Phase 3 | COMPLETED | 441 |
| [NCT07574723](https://clinicaltrials.gov/study/NCT07574723) | Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity | Obesity | Not phased | RECRUITING | 68 |
| [NCT07423247](https://clinicaltrials.gov/study/NCT07423247) | Tirzepatide (Spartina) in Obese Kidney Transplant Recipients | Tirzepatide | Phase 4 | RECRUITING | 30 |
| [NCT07228741](https://clinicaltrials.gov/study/NCT07228741) | Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity | Acute Lymphoblastic Leukemia, Obesity | Phase 2 | RECRUITING | 20 |
| [NCT05691712](https://clinicaltrials.gov/study/NCT05691712) | A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes | Diabetes Type 2, Diabetes Mellitus | Phase 3 | COMPLETED | 257 |
| [NCT06534411](https://clinicaltrials.gov/study/NCT06534411) | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | Diabetes Mellitus, Type 2 | Phase 3 | COMPLETED | 1023 |
| [NCT07244458](https://clinicaltrials.gov/study/NCT07244458) | Dietary Peanuts and Nutrition-Related Outcomes | Dietary Change, Obesity & Overweight | Not phased | RECRUITING | 64 |
| [NCT06009653](https://clinicaltrials.gov/study/NCT06009653) | Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity | Obesity, Metabolic Disease | Phase 4 | WITHDRAWN | 0 |
| [NCT04184622](https://clinicaltrials.gov/study/NCT04184622) | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | Overweight, Obesity | Phase 3 | COMPLETED | 2539 |
| [NCT07483801](https://clinicaltrials.gov/study/NCT07483801) | DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | Cardiovascular Diseases | Phase 4 | NOT_YET_RECRUITING | 112 |
| [NCT07685834](https://clinicaltrials.gov/study/NCT07685834) | Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss | Lax Skin | Not phased | ACTIVE_NOT_RECRUITING | 30 |
| [NCT06584916](https://clinicaltrials.gov/study/NCT06584916) | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | Obesity, Overweight | Phase 3 | COMPLETED | 376 |
| [NCT07373834](https://clinicaltrials.gov/study/NCT07373834) | Tirzepatide and Muscle Outcomes in Obesity | Obesity (Disorder) | Not phased | RECRUITING | 30 |
| [NCT05177653](https://clinicaltrials.gov/study/NCT05177653) | Separate and Combined Extrapancreatic Effects of the Incretin Hormones | Pancreatectomy; Hyperglycemia | Not phased | COMPLETED | 13 |
| [NCT06635057](https://clinicaltrials.gov/study/NCT06635057) | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan | Type 2 Diabetes | Phase 4 | COMPLETED | 166 |
| [NCT04004988](https://clinicaltrials.gov/study/NCT04004988) | A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants | Healthy | Phase 1 | COMPLETED | 47 |
| [NCT07602699](https://clinicaltrials.gov/study/NCT07602699) | Multi-Site Trial of Tirzepatide for Smoking Cessation | Smoking Cessation, Smoking Behaviors | Phase 2 | RECRUITING | 300 |
| [NCT07165028](https://clinicaltrials.gov/study/NCT07165028) | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Metabolic Dysfunction-Associated Steatotic Liver Disease | Phase 3 | RECRUITING | 4500 |
| [NCT05963022](https://clinicaltrials.gov/study/NCT05963022) | A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) | Type 2 Diabetes | Phase 3 | COMPLETED | 206 |
| [NCT06037252](https://clinicaltrials.gov/study/NCT06037252) | A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity | Type 2 Diabetes, Obesity | Phase 2 | ACTIVE_NOT_RECRUITING | 414 |
| [NCT07573163](https://clinicaltrials.gov/study/NCT07573163) | Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion | Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status | Phase 2 | NOT_YET_RECRUITING | 34 |
| [NCT06857942](https://clinicaltrials.gov/study/NCT06857942) | A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Psoriasis, Overweight or Obesity | Phase 4 | RECRUITING | 200 |
| [NCT07078838](https://clinicaltrials.gov/study/NCT07078838) | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | Endometrial Cancer, Endometrial Intraepithelial Neoplasia | Phase 2 | NOT_YET_RECRUITING | 40 |
| [NCT03882970](https://clinicaltrials.gov/study/NCT03882970) | A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 1444 |
| [NCT06515418](https://clinicaltrials.gov/study/NCT06515418) | Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over | Obesity | Phase 2 | TERMINATED | 204 |
| [NCT07382024](https://clinicaltrials.gov/study/NCT07382024) | Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation | Atrial Fibrillation Ablation, Persistent Atrial Fibrillation | Not phased | NOT_YET_RECRUITING | 200 |
| [NCT04407234](https://clinicaltrials.gov/study/NCT04407234) | A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide | Overweight, Obesity | Phase 1 | COMPLETED | 36 |
| [NCT07555730](https://clinicaltrials.gov/study/NCT07555730) | AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) | Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance | Phase 4 | NOT_YET_RECRUITING | 400 |
| [NCT04657016](https://clinicaltrials.gov/study/NCT04657016) | A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program | Obesity, Overweight | Phase 3 | COMPLETED | 579 |
| [NCT07676331](https://clinicaltrials.gov/study/NCT07676331) | Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial | Hormone-receptor-positive Breast Cancer, Early Breast Cancer | Phase 2 | NOT_YET_RECRUITING | 168 |
| [NCT06737042](https://clinicaltrials.gov/study/NCT06737042) | Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants | Obesity and Overweight | Phase 2 | COMPLETED | 326 |
| [NCT03311724](https://clinicaltrials.gov/study/NCT03311724) | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 2 | COMPLETED | 111 |
| [NCT07000955](https://clinicaltrials.gov/study/NCT07000955) | Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Obesity | Phase 2 | ACTIVE_NOT_RECRUITING | 98 |
| [NCT04311424](https://clinicaltrials.gov/study/NCT04311424) | Study of Tirzepatide in Healthy Participants | Healthy | Phase 1 | COMPLETED | 6 |
| [NCT06373146](https://clinicaltrials.gov/study/NCT06373146) | A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Obesity | Phase 2 | COMPLETED | 392 |
| [NCT07468552](https://clinicaltrials.gov/study/NCT07468552) | Trial of Tirzepatide for the Treatment of Cannabis Use Disorder | Cannabis Use Disorder | Phase 2 | NOT_YET_RECRUITING | 100 |
| [NCT06131437](https://clinicaltrials.gov/study/NCT06131437) | A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | Obesity | Phase 3 | COMPLETED | 809 |
| [NCT06976853](https://clinicaltrials.gov/study/NCT06976853) | Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | Crohn Disease (CD) | Phase 2 | RECRUITING | 60 |
| [NCT03940742](https://clinicaltrials.gov/study/NCT03940742) | A Study of Tirzepatide in Participants With Impaired Liver Function | Hepatic Insufficiency | Phase 1 | COMPLETED | 32 |
| [NCT06588296](https://clinicaltrials.gov/study/NCT06588296) | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Psoriatic Arthritis, Obesity | Phase 3 | COMPLETED | 279 |
| [NCT06374875](https://clinicaltrials.gov/study/NCT06374875) | Fibrosis Lessens After Metabolic Surgery | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease | Phase 4 | RECRUITING | 120 |
| [NCT05556512](https://clinicaltrials.gov/study/NCT05556512) | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Obesity, Overweight | Phase 3 | ACTIVE_NOT_RECRUITING | 15374 |
| [NCT07728812](https://clinicaltrials.gov/study/NCT07728812) | Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy | Obesity & Overweight | Not phased | NOT_YET_RECRUITING | 424 |
| [NCT07046819](https://clinicaltrials.gov/study/NCT07046819) | Tirzepatide in MetALD | Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder | Phase 2 | RECRUITING | 120 |
| [NCT05696847](https://clinicaltrials.gov/study/NCT05696847) | A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity | Obesity | Phase 1 | COMPLETED | 28 |
| [NCT05536804](https://clinicaltrials.gov/study/NCT05536804) | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight, Obesity | Phase 2 | ACTIVE_NOT_RECRUITING | 140 |
| [NCT06901349](https://clinicaltrials.gov/study/NCT06901349) | A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes | Obesity, Overweight | Phase 2 | WITHDRAWN | 0 |
| [NCT04657003](https://clinicaltrials.gov/study/NCT04657003) | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | Type 2 Diabetes, Overweight | Phase 3 | COMPLETED | 938 |
| [NCT06734273](https://clinicaltrials.gov/study/NCT06734273) | Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss | Obesity and Obesity-related Medical Conditions | Phase 1 | RECRUITING | 42 |
| [NCT06885736](https://clinicaltrials.gov/study/NCT06885736) | LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy | Obesity | Not phased | RECRUITING | 232 |
| [NCT03954834](https://clinicaltrials.gov/study/NCT03954834) | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 478 |
| [NCT04844918](https://clinicaltrials.gov/study/NCT04844918) | A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease | Obesity | Phase 3 | COMPLETED | 267 |
| [NCT04050553](https://clinicaltrials.gov/study/NCT04050553) | A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2, Hypoglycemia | Phase 1 | COMPLETED | 42 |
| [NCT07630454](https://clinicaltrials.gov/study/NCT07630454) | Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF | Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 4 | NOT_YET_RECRUITING | 602 |
| [NCT06700538](https://clinicaltrials.gov/study/NCT06700538) | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Obesity | Phase 2 | RECRUITING | 180 |
| [NCT06895408](https://clinicaltrials.gov/study/NCT06895408) | Separate and Combined Extrapancreatic Effects of GIP and GLP-1 | Pancreatectomy; Hyperglycemia | Not phased | COMPLETED | 12 |
| [NCT06143956](https://clinicaltrials.gov/study/NCT06143956) | A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Obesity, Overweight | Phase 2 | RECRUITING | 1481 |
| [NCT05751720](https://clinicaltrials.gov/study/NCT05751720) | Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue | Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis | Phase 2 | UNKNOWN | 30 |
| [NCT06937099](https://clinicaltrials.gov/study/NCT06937099) | Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Crohn's Disease, Obesity or Overweight | Phase 3 | RECRUITING | 290 |
| [NCT07303556](https://clinicaltrials.gov/study/NCT07303556) | Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs | Heart Failure, Diabete Type 2 | Not phased | ACTIVE_NOT_RECRUITING | 120 |
| [NCT07536516](https://clinicaltrials.gov/study/NCT07536516) | Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients | Diabetes Mellitus | Not phased | RECRUITING | 20 |
| [NCT07257484](https://clinicaltrials.gov/study/NCT07257484) | Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | Obesity (Disorder), Breast Cancer | Phase 4 | RECRUITING | 30 |
| [NCT03861039](https://clinicaltrials.gov/study/NCT03861039) | A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 443 |
| [NCT06811324](https://clinicaltrials.gov/study/NCT06811324) | Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults | Obesity Prevention, Sarcopenia in Elderly | Phase 2 | RECRUITING | 20 |
| [NCT06662383](https://clinicaltrials.gov/study/NCT06662383) | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 800 |
| [NCT05706506](https://clinicaltrials.gov/study/NCT05706506) | A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) | Type 2 Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | COMPLETED | 152 |
| [NCT06451458](https://clinicaltrials.gov/study/NCT06451458) | ECHO for Diabetes and Multiple Chronic Conditions Study | Diabetes Mellitus, Chronic Disease | Not phased | ENROLLING_BY_INVITATION | 20 |
| [NCT07298915](https://clinicaltrials.gov/study/NCT07298915) | The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | Obesity & Overweight | Phase 3 | NOT_YET_RECRUITING | 24 |
| [NCT04311411](https://clinicaltrials.gov/study/NCT04311411) | A Study of Tirzepatide in Overweight and Very Overweight Participants | Obesity, Overweight | Phase 1 | COMPLETED | 114 |
| [NCT07213323](https://clinicaltrials.gov/study/NCT07213323) | Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment | Obesity &Amp; Overweight, Digestive Disorders | Not phased | NOT_YET_RECRUITING | 50 |
| [NCT07284511](https://clinicaltrials.gov/study/NCT07284511) | A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar | Type 1 Diabetes, Type 1 Diabetes Mellitus | Phase 3 | RECRUITING | 105 |
| [NCT06965413](https://clinicaltrials.gov/study/NCT06965413) | A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity | Obesity, Overweight | Phase 2 | ACTIVE_NOT_RECRUITING | 285 |
| [NCT06790225](https://clinicaltrials.gov/study/NCT06790225) | Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA) | Bone Disease, Metabolic, Diabetes Mellitus, Type 2 | Not phased | RECRUITING | 12 |
| [NCT07326111](https://clinicaltrials.gov/study/NCT07326111) | A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese | Polycystic Ovary Syndrome (PCOS), Obesity & Overweight | Phase 4 | RECRUITING | 198 |
| [NCT07027969](https://clinicaltrials.gov/study/NCT07027969) | Metabolic Surgery for Atrial Fibrillation Elimination | Atrial Fibrillation, Obesity and Obesity-related Medical Conditions | Phase 4 | NOT_YET_RECRUITING | 100 |
| [NCT07319975](https://clinicaltrials.gov/study/NCT07319975) | Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity | Obesity | Not phased | NOT_YET_RECRUITING | 48 |
| [NCT07728318](https://clinicaltrials.gov/study/NCT07728318) | Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Not phased | NOT_YET_RECRUITING | 52 |
| [NCT07715929](https://clinicaltrials.gov/study/NCT07715929) | Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients | Atrial Fibrillation, Obesity & Overweight | Phase 4 | NOT_YET_RECRUITING | 710 |
| [NCT04847557](https://clinicaltrials.gov/study/NCT04847557) | A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 3 | COMPLETED | 731 |
| [NCT07065552](https://clinicaltrials.gov/study/NCT07065552) | Tirzepatide in Obesity-Driven Endometrial Cancer | Endometrial Cancer, Obesity | Phase 1 | RECRUITING | 20 |
| [NCT07179120](https://clinicaltrials.gov/study/NCT07179120) | Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health | Obesity-related Male Infertility | Phase 2 | NOT_YET_RECRUITING | 180 |
| [NCT06937086](https://clinicaltrials.gov/study/NCT06937086) | Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Ulcerative Colitis, Obesity or Overweight | Phase 3 | RECRUITING | 350 |
| [NCT06847399](https://clinicaltrials.gov/study/NCT06847399) | Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder | Obesity and Overweight, Binge Eating Disorder | Phase 2 | RECRUITING | 105 |
| [NCT06962280](https://clinicaltrials.gov/study/NCT06962280) | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes, Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 465 |
| [NCT04039503](https://clinicaltrials.gov/study/NCT04039503) | A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin | Type 2 Diabetes | Phase 3 | COMPLETED | 475 |
| [NCT07223242](https://clinicaltrials.gov/study/NCT07223242) | Tailored Exercise Training Study Among Adults With HFpEF | HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies | Phase 3 | RECRUITING | 120 |
| [NCT06648031](https://clinicaltrials.gov/study/NCT06648031) | Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | Type2diabetes | Phase 1 | COMPLETED | 148 |
| [NCT07107334](https://clinicaltrials.gov/study/NCT07107334) | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | Endometrioid Endometrial Adenocarcinoma | Phase 2 | RECRUITING | 20 |
| [NCT06820281](https://clinicaltrials.gov/study/NCT06820281) | Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Type 1 Diabetes Mellitus | Phase 2 | NOT_YET_RECRUITING | 44 |
| [NCT07697391](https://clinicaltrials.gov/study/NCT07697391) | AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes | Obesity, Diabetes Mellitus, Type 2 | Phase 4 | NOT_YET_RECRUITING | 285 |
| [NCT03861052](https://clinicaltrials.gov/study/NCT03861052) | A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | COMPLETED | 636 |
| [NCT07633639](https://clinicaltrials.gov/study/NCT07633639) | GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | Obesity | Not phased | RECRUITING | 200 |
| [NCT07438444](https://clinicaltrials.gov/study/NCT07438444) | A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | Diabetes Mellitus, Type 2, Obesity | Phase 4 | RECRUITING | 344 |
| [NCT06651177](https://clinicaltrials.gov/study/NCT06651177) | Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Opioid Use Disorder, Opioid Use Disorder, Moderate | Phase 2 | RECRUITING | 310 |
| [NCT07605247](https://clinicaltrials.gov/study/NCT07605247) | Tirzepatide in the Treatment of Endometrial Cancer | Endometrial Cancer | Phase 2 | NOT_YET_RECRUITING | 30 |
| [NCT06518837](https://clinicaltrials.gov/study/NCT06518837) | Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer | Phase 2 | RECRUITING | 40 |
| [NCT06745128](https://clinicaltrials.gov/study/NCT06745128) | Tirzepatide for Obesity and Meth Use Disorder | Obesity, Methamphetamine Use Disorder | Phase 2 | ACTIVE_NOT_RECRUITING | 45 |
| [NCT05078255](https://clinicaltrials.gov/study/NCT05078255) | The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes | Type 2 Diabetes, Obesity | Not phased | COMPLETED | 61 |
| [NCT06326047](https://clinicaltrials.gov/study/NCT06326047) | A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 299 |
| [NCT06734312](https://clinicaltrials.gov/study/NCT06734312) | MAINTAIN (Mucosal AblatIoN Therapy After INcretins) | Obesity and Obesity-related Medical Conditions, Obesity and Overweight | Not phased | RECRUITING | 20 |
| [NCT07226947](https://clinicaltrials.gov/study/NCT07226947) | Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment | Obesity, Body Composition | Not phased | RECRUITING | 100 |
| [NCT07521631](https://clinicaltrials.gov/study/NCT07521631) | Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Obesity | Phase 2 | RECRUITING | 372 |
| [NCT06721507](https://clinicaltrials.gov/study/NCT06721507) | 2024 Tirzepatide-Bariatric Surgery | Obesity and Obesity-related Medical Conditions, Bariatric Surgery | Phase 4 | RECRUITING | 50 |
| [NCT06916065](https://clinicaltrials.gov/study/NCT06916065) | A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity | Overweight, Obesity | Phase 1 | COMPLETED | 188 |
| [NCT07091734](https://clinicaltrials.gov/study/NCT07091734) | Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024 | Lipodystrophy, Partial | Phase 2 | RECRUITING | 32 |
| [NCT03951753](https://clinicaltrials.gov/study/NCT03951753) | A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 117 |
| [NCT07671248](https://clinicaltrials.gov/study/NCT07671248) | Tirzepatide in the Treatment of Cannabis Use Disorder | Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe | Phase 3 | NOT_YET_RECRUITING | 15 |
| [NCT07095517](https://clinicaltrials.gov/study/NCT07095517) | Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors | Colorectal Cancer Prevention, Colorectal Adenoma | Phase 1 | RECRUITING | 20 |
| [NCT07247084](https://clinicaltrials.gov/study/NCT07247084) | A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) | Obesity | Phase 4 | RECRUITING | 3000 |
| [NCT07554638](https://clinicaltrials.gov/study/NCT07554638) | Incretin Therapies in Obesity-related HFpEF | Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction | Phase 4 | NOT_YET_RECRUITING | 50 |
| [NCT06439277](https://clinicaltrials.gov/study/NCT06439277) | A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Obesity, Weight Gain | Phase 3 | RECRUITING | 300 |
| [NCT07245771](https://clinicaltrials.gov/study/NCT07245771) | Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity | Obesity &Amp; Overweight | Phase 2 | RECRUITING | 104 |
| [NCT07701460](https://clinicaltrials.gov/study/NCT07701460) | Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1 | Weight Maintenance | Not phased | NOT_YET_RECRUITING | 200 |
| [NCT06180616](https://clinicaltrials.gov/study/NCT06180616) | Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity | Type 1 Diabetes Mellitus, Overweight and Obesity | Phase 2 | NOT_YET_RECRUITING | 40 |
| [NCT07202247](https://clinicaltrials.gov/study/NCT07202247) | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | RECRUITING | 60 |
| [NCT07194317](https://clinicaltrials.gov/study/NCT07194317) | A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment | Obese Patients | Not phased | COMPLETED | 64 |
| [NCT04235959](https://clinicaltrials.gov/study/NCT04235959) | A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 24 |
| [NCT06533527](https://clinicaltrials.gov/study/NCT06533527) | Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Diabetes Mellitus, Type 2, Obesity | Phase 4 | COMPLETED | 69 |
| [NCT06802081](https://clinicaltrials.gov/study/NCT06802081) | TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation | Atrial Fibrillation, Obesity | Phase 2 | RECRUITING | 100 |
| [NCT06914895](https://clinicaltrials.gov/study/NCT06914895) | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes, Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 905 |
| [NCT06484114](https://clinicaltrials.gov/study/NCT06484114) | Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide | Obesity, Weight Change Trajectory | Not phased | ACTIVE_NOT_RECRUITING | 315 |
| [NCT06326060](https://clinicaltrials.gov/study/NCT06326060) | A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight | Obesity | Phase 2 | COMPLETED | 354 |
| [NCT07244445](https://clinicaltrials.gov/study/NCT07244445) | Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy | Dietary Change, Obesity & Overweight | Not phased | RECRUITING | 108 |
| [NCT07635953](https://clinicaltrials.gov/study/NCT07635953) | New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes | Diabetes Mellitus | Phase 3 | NOT_YET_RECRUITING | 296 |
| [NCT06727331](https://clinicaltrials.gov/study/NCT06727331) | Study of Tirzepatide for Recovery and Alcohol Use Management | Alcohol Use Disorder (AUD) | Phase 2 | RECRUITING | 20 |
| [NCT03375463](https://clinicaltrials.gov/study/NCT03375463) | A Study of Tirzepatide (LY3298176) in Healthy Participants | Healthy | Phase 1 | COMPLETED | 52 |
| [NCT04660643](https://clinicaltrials.gov/study/NCT04660643) | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss | Obesity, Overweight | Phase 3 | COMPLETED | 783 |
| [NCT06911203](https://clinicaltrials.gov/study/NCT06911203) | A Study of BGM0504 in Participants With Obesity | Obesity | Phase 2 | RECRUITING | 90 |
| [NCT04172987](https://clinicaltrials.gov/study/NCT04172987) | A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants | Healthy | Phase 1 | COMPLETED | 40 |
| [NCT05564039](https://clinicaltrials.gov/study/NCT05564039) | A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) | Type 2 Diabetes | Phase 4 | COMPLETED | 282 |
| [NCT06897475](https://clinicaltrials.gov/study/NCT06897475) | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Type 2 Diabetes | Phase 2 | RECRUITING | 240 |
| [NCT05933499](https://clinicaltrials.gov/study/NCT05933499) | Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity | Obesity | Phase 2 | RECRUITING | 63 |
| [NCT07387796](https://clinicaltrials.gov/study/NCT07387796) | Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation | Drug Discontinuation, Substance Use Disorders | Not phased | RECRUITING | 40 |
| [NCT06934642](https://clinicaltrials.gov/study/NCT06934642) | Effect of Tirzepatide on Markers of MASLD in Patients With Obesity | MASLD, Obesity | Phase 1 | RECRUITING | 8 |
| [NCT06345066](https://clinicaltrials.gov/study/NCT06345066) | A Study of LY3841136 in Overweight and Obese Participants | Obesity, Overweight | Phase 1 | COMPLETED | 96 |
| [NCT06565611](https://clinicaltrials.gov/study/NCT06565611) | A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | Obesity | Phase 2 | ACTIVE_NOT_RECRUITING | 108 |
| [NCT06937203](https://clinicaltrials.gov/study/NCT06937203) | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Obesity, Diabetes Mellitus, Type 2 | Phase 2 | RECRUITING | 150 |
| [NCT05024032](https://clinicaltrials.gov/study/NCT05024032) | A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) | Obesity, Overweight | Phase 3 | COMPLETED | 210 |
| [NCT03987919](https://clinicaltrials.gov/study/NCT03987919) | A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | COMPLETED | 1879 |
| [NCT06640972](https://clinicaltrials.gov/study/NCT06640972) | Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists | Triglycerides, Weight Gain Trajectory | Phase 2 | COMPLETED | 68 |
| [NCT06575738](https://clinicaltrials.gov/study/NCT06575738) | Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents | Obesity, Adolescent Obesity | Phase 1 | RECRUITING | 40 |
| [NCT06901245](https://clinicaltrials.gov/study/NCT06901245) | Tirzepatide in PWS, HO and GNSO | Prader-Willi Syndrome, Hypothalamic Obesity | Phase 4 | RECRUITING | 36 |
| [NCT06759701](https://clinicaltrials.gov/study/NCT06759701) | Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | Diabetes, Prostate Cancer | Phase 1 | RECRUITING | 30 |
| [NCT06221969](https://clinicaltrials.gov/study/NCT06221969) | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Type 2 Diabetes | Phase 3 | COMPLETED | 1024 |
| [NCT06803888](https://clinicaltrials.gov/study/NCT06803888) | Bariatric Surgery vs. Semaglutide vs. Tirzepatide | Obesity and Obesity-related Medical Conditions | Phase 4 | ACTIVE_NOT_RECRUITING | 125 |
| [NCT07299084](https://clinicaltrials.gov/study/NCT07299084) | A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2, Overweight | Phase 1 | ACTIVE_NOT_RECRUITING | 40 |
| [NCT07559500](https://clinicaltrials.gov/study/NCT07559500) | Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | Alcohol Use Disorder (AUD) | Phase 1 | RECRUITING | 176 |
| [NCT06606821](https://clinicaltrials.gov/study/NCT06606821) | The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease | Coronary Artery Disease, Coronary Microvascular Dysfunction | Phase 4 | RECRUITING | 124 |
| [NCT06603571](https://clinicaltrials.gov/study/NCT06603571) | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Obesity, Overweight | Phase 2 | ACTIVE_NOT_RECRUITING | 367 |
| [NCT07527910](https://clinicaltrials.gov/study/NCT07527910) | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 2 | RECRUITING | 204 |
| [NCT07191873](https://clinicaltrials.gov/study/NCT07191873) | Tirzepatide in Idiopathic Intracranial Hypertension Trial | Idiopathic Intracranial Hypertension (IIH) | Phase 4 | NOT_YET_RECRUITING | 60 |
| [NCT07588438](https://clinicaltrials.gov/study/NCT07588438) | Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | Obesity, Diabetes Mellitus, Type 2 | Phase 4 | RECRUITING | 160 |
| [NCT05659368](https://clinicaltrials.gov/study/NCT05659368) | Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1 | Wolfram Syndrome | Phase 2 | UNKNOWN | 10 |
| [NCT03131687](https://clinicaltrials.gov/study/NCT03131687) | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 318 |
| [NCT06751589](https://clinicaltrials.gov/study/NCT06751589) | A Study of a Weight Loss Intervention in People With Endometrial Cancer | Endometrial Cancer | Phase 1 | RECRUITING | 36 |
| [NCT07368855](https://clinicaltrials.gov/study/NCT07368855) | GLP-1 Medicines and Mental Health Changes | Obesity, Depression | Not phased | COMPLETED | 90 |
| [NCT06994338](https://clinicaltrials.gov/study/NCT06994338) | Tirzepatide for Alcohol Use Disorder | Alcohol Use Disorder, Obesity and Overweight | Phase 2 | RECRUITING | 42 |
| [NCT07589322](https://clinicaltrials.gov/study/NCT07589322) | Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | Obesity and Metabolic Syndrome | Not phased | RECRUITING | 120 |
| [NCT06297616](https://clinicaltrials.gov/study/NCT06297616) | A Study of LY3841136 in Japanese Participants With Obesity or Overweight | Obesity, Overweight | Phase 1 | COMPLETED | 128 |
| [NCT07457437](https://clinicaltrials.gov/study/NCT07457437) | Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment | Muscle Mass and Strength, Obesity & Overweight | Not phased | RECRUITING | 60 |
| [NCT07057310](https://clinicaltrials.gov/study/NCT07057310) | Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Obesity, Menopause | Phase 4 | ENROLLING_BY_INVITATION | 30 |
| [NCT04050670](https://clinicaltrials.gov/study/NCT04050670) | A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes | Healthy | Phase 1 | COMPLETED | 54 |
| [NCT07176663](https://clinicaltrials.gov/study/NCT07176663) | Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure | Obesity | Not phased | NOT_YET_RECRUITING | 15 |
| [NCT05810597](https://clinicaltrials.gov/study/NCT05810597) | A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices | Healthy | Phase 1 | COMPLETED | 65 |
| [NCT02759107](https://clinicaltrials.gov/study/NCT02759107) | A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) | Healthy, Type 2 Diabetes Mellitus (T2DM) | Phase 1 | COMPLETED | 142 |
| [NCT05433584](https://clinicaltrials.gov/study/NCT05433584) | A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 4 | ACTIVE_NOT_RECRUITING | 780 |
| [NCT06861439](https://clinicaltrials.gov/study/NCT06861439) | GLP-1s to Enhance Lasting Optimal Weight | Obesity | Phase 4 | ACTIVE_NOT_RECRUITING | 40 |
| [NCT06445075](https://clinicaltrials.gov/study/NCT06445075) | Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese | Overweight and Obesity | Phase 2 | COMPLETED | 102 |
| [NCT06075667](https://clinicaltrials.gov/study/NCT06075667) | A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity, Overweight | Phase 3 | ACTIVE_NOT_RECRUITING | 160 |
| [NCT07481747](https://clinicaltrials.gov/study/NCT07481747) | Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | Phase 3 | RECRUITING | 2539 |
| [NCT06605703](https://clinicaltrials.gov/study/NCT06605703) | A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) | Obesity, Overweight | Phase 4 | COMPLETED | 226 |
| [NCT03730662](https://clinicaltrials.gov/study/NCT03730662) | A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 2002 |
| [NCT05582096](https://clinicaltrials.gov/study/NCT05582096) | A Study of LY3457263 in Obese Participants | Overweight, Obesity | Phase 1 | COMPLETED | 38 |
| [NCT06939088](https://clinicaltrials.gov/study/NCT06939088) | Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder | Alcohol Use Disorder, Alcohol Abuse/Dependence | Phase 2 | RECRUITING | 108 |
| [NCT06630585](https://clinicaltrials.gov/study/NCT06630585) | GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes | Type 1 Diabetes (T1D) | Phase 3 | RECRUITING | 42 |
| [NCT05412004](https://clinicaltrials.gov/study/NCT05412004) | Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Obstructive Sleep Apnea, Obesity | Phase 3 | COMPLETED | 469 |
| [NCT04093752](https://clinicaltrials.gov/study/NCT04093752) | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) | Type 2 Diabetes | Phase 3 | COMPLETED | 917 |
| [NCT06732245](https://clinicaltrials.gov/study/NCT06732245) | Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | Obesity and Overweight | Phase 2 | NOT_YET_RECRUITING | 224 |
| [NCT07349641](https://clinicaltrials.gov/study/NCT07349641) | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | Phase 2 | NOT_YET_RECRUITING | 55 |
| [NCT05990374](https://clinicaltrials.gov/study/NCT05990374) | Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years | Diabetes | Not phased | UNKNOWN | 100 |
| [NCT07364175](https://clinicaltrials.gov/study/NCT07364175) | A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults | Hypertension, Obesity & Overweight | Not phased | RECRUITING | 60 |
| [NCT06935838](https://clinicaltrials.gov/study/NCT06935838) | Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV | Obesity and Overweight, HIV | Phase 2 | COMPLETED | 12 |
| [NCT07557355](https://clinicaltrials.gov/study/NCT07557355) | A Study of SRSD384 in Overweight or Obese Participants | Overweight , Obesity | Phase 2 | NOT_YET_RECRUITING | 78 |
| [NCT04537923](https://clinicaltrials.gov/study/NCT04537923) | A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin | Type 2 Diabetes | Phase 3 | COMPLETED | 1428 |
| [NCT07218445](https://clinicaltrials.gov/study/NCT07218445) | The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity | Obesity, Menopause Hot Flashes | Phase 4 | RECRUITING | 40 |
| [NCT05978713](https://clinicaltrials.gov/study/NCT05978713) | A Study of Tirzepatide (LY3298176) in Healthy Lactating Females | Healthy | Phase 1 | COMPLETED | 11 |
| [NCT06301256](https://clinicaltrials.gov/study/NCT06301256) | Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa | Hidradenitis Suppurativa | Not phased | UNKNOWN | 20 |
| [NCT07128082](https://clinicaltrials.gov/study/NCT07128082) | The Long COVID Treatment Trial | Long COVID | Phase 2 | ACTIVE_NOT_RECRUITING | 1000 |
| [NCT06918405](https://clinicaltrials.gov/study/NCT06918405) | Efficacy and Safety of Tirzepatide for Weight Management | Obesity and Obesity-related Medical Conditions | Phase 3 | ACTIVE_NOT_RECRUITING | 440 |
| [NCT06588283](https://clinicaltrials.gov/study/NCT06588283) | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Psoriasis, Obesity | Phase 3 | COMPLETED | 281 |
| [NCT06854614](https://clinicaltrials.gov/study/NCT06854614) | Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) | Obesity | Phase 4 | ACTIVE_NOT_RECRUITING | 150 |
| [NCT04166773](https://clinicaltrials.gov/study/NCT04166773) | A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 190 |
| [NCT06643728](https://clinicaltrials.gov/study/NCT06643728) | A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight | Obesity, Overweight | Phase 2 | ACTIVE_NOT_RECRUITING | 252 |
| [NCT05822544](https://clinicaltrials.gov/study/NCT05822544) | Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes | Healthy Subjects, Obesity | Phase 1 | RECRUITING | 564 |
| [NCT06162715](https://clinicaltrials.gov/study/NCT06162715) | GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | Severe Obesity, Obesity | Phase 3 | ENROLLING_BY_INVITATION | 30 |
| [NCT03322631](https://clinicaltrials.gov/study/NCT03322631) | A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 1 | COMPLETED | 48 |
| [NCT06864026](https://clinicaltrials.gov/study/NCT06864026) | A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Psoriatic Arthritis, Overweight or Obesity | Phase 4 | RECRUITING | 200 |
| [NCT07619989](https://clinicaltrials.gov/study/NCT07619989) | Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists | Obesity & Overweight | Not phased | RECRUITING | 24 |
| [NCT06774079](https://clinicaltrials.gov/study/NCT06774079) | Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients | Crohn Disease | Phase 4 | RECRUITING | 24 |
| [NCT07463846](https://clinicaltrials.gov/study/NCT07463846) | A Study to Evaluate ALN-2232 in Participants With Obesity | Obesity | Phase 2 | RECRUITING | 156 |
| [NCT07096908](https://clinicaltrials.gov/study/NCT07096908) | Tirzepatide Use in People With Obesity and Type 1 Diabetes | Type1diabetes, Obesity | Phase 4 | RECRUITING | 60 |
| [NCT07609160](https://clinicaltrials.gov/study/NCT07609160) | Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals | Obesity, Sarcopenia | Not phased | NOT_YET_RECRUITING | 108 |
| [NCT04081337](https://clinicaltrials.gov/study/NCT04081337) | A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide | Obesity | Phase 1 | COMPLETED | 55 |
| [NCT07220473](https://clinicaltrials.gov/study/NCT07220473) | Tirzepatide to Slow Biological Aging | Aging, LONGEVITY 1 | Phase 2 | RECRUITING | 90 |

## Common questions

**How many human trials does Tirzepatide have?**
234, each listed above with a link to its original record.

**Is Tirzepatide FDA approved?**
Yes — FDA-approved for type 2 diabetes and chronic weight management.

**Where does this data come from?**
ClinicalTrials.gov. We count interventional human studies only. Every trial
links to its original record.

---

*Automated aggregation from public registries. Not medical advice. No physician
has reviewed this page. Source: https://www.whatsactuallyknown.com/compounds/tirzepatide*